1. Home
  2. BWA vs JAZZ Comparison

BWA vs JAZZ Comparison

Compare BWA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BorgWarner Inc.

BWA

BorgWarner Inc.

HOLD

Current Price

$56.59

Market Cap

11.2B

ML Signal

HOLD

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

HOLD

Current Price

$202.48

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWA
JAZZ
Founded
1987
2003
Country
United States
Ireland
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
10.4B
IPO Year
1995
2007

Fundamental Metrics

Financial Performance
Metric
BWA
JAZZ
Price
$56.59
$202.48
Analyst Decision
Buy
Strong Buy
Analyst Count
15
14
Target Price
$59.33
$217.57
AVG Volume (30 Days)
1.5M
832.5K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
1.25%
N/A
EPS Growth
N/A
N/A
EPS
1.28
N/A
Revenue
$14,316,000,000.00
$1,618,693,000.00
Revenue This Year
$1.54
$6.22
Revenue Next Year
$3.54
$7.68
P/E Ratio
$44.52
N/A
Revenue Growth
1.63
N/A
52 Week Low
$28.92
$105.00
52 Week High
$70.08
$207.48

Technical Indicators

Market Signals
Indicator
BWA
JAZZ
Relative Strength Index (RSI) 57.48 58.73
Support Level $51.43 $194.77
Resistance Level $70.08 $207.48
Average True Range (ATR) 1.52 5.09
MACD 0.16 -0.29
Stochastic Oscillator 81.06 60.62

Price Performance

Historical Comparison
BWA
JAZZ

About BWA BorgWarner Inc.

BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: